Sign in with Google. Opens in new tab
ENTITY
Novavax

Novavax (NVAX US)

24
Analysis
Health CareUnited States
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
more
12 Feb 2022 15:40

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new  uses in agriculture, industry, and as potential new therapeutics to replace or...

Logo
358 Views
Share
28 May 2025 12:22Broker

Biopharma Week in Review - FDA Provides Some Certainty for Vaccines; ASCO Abstracts Snippets

Vaccine stocks (NVAX, BNTX, PFE, MRNA, PCVX) had a good week, as the FDA provided new regulatory policy for COVID-19 vaccines.

Logo
162 Views
Share
21 May 2025 11:39Issuer-paid

Biopharma Week in Review MFN Fears Overdone but Medicare Negotiation Changes Reapplied Pressure

President Trump’s MFN executive order lacked a clear plan to lower drug prices, with any immediate moves likely facing legal challenges.

Logo
195 Views
Share
06 May 2025 12:39Issuer-paid

Biopharma Week in Review - Macro and M&A Boost Biotech; NVO Moves to Slow LLY Obesity Lead

Biotech fared better than pharma, as macro trends mostly favored growth stocks and LLY weakness pressured the large cap group.

Logo
181 Views
Share
28 Apr 2025 21:26Issuer-paid

Biopharma Week in Review: Makary Sparked FDA Optimism; Growing Pushback on HHS Changes

FDA Commissioner Martin Makary injected some regulatory optimism with his first public comments, advocating for accelerated drug approval pathways.

Logo
172 Views
Share
x